文献速递临床免疫临床生化

循环胶质纤维酸性蛋白与神经丝轻链在重症肌无力中的作用探索

Exploring the role of circulating glial fibrillary acidic protein and neurofilament light chain in myasthenia gravis.
PubMed 文献 · Clin Chim Acta · 2026-05-02

该回顾性病例对照研究纳入137例确诊重症肌无力患者和338例健康对照,采用化学发光免疫分析法检测血清GFAP和NfL浓度。结果显示GFAP在患者中升高但主要由年龄驱动,诊断性能中等(AUC=0.704);NfL仅轻度升高,提示二者反映非特异性神经生物学过程而非可靠的MG生物标志物。

要点

  • 血清GFAP在MG患者中升高(44.6 vs 29.6 pg/mL),但与年龄强相关(r=0.64),多变量回归中年龄是独立决定因素而非MG状态。
  • GFAP诊断MG的AUC为0.704,性能中等,受年龄和性别混杂影响,诊断效用有限。
  • 年龄性别匹配分析中NfL在MG患者中轻度升高(30.2 vs 15.5 pg/mL,p=0.047),临床相关性尚不明确。

核心结论

  • 循环GFAP在MG中升高但主要由年龄和性别驱动,而非疾病特异性机制,限制其诊断效用。
  • NfL仅轻度升高,提示可能存在轻微神经轴索受累,但临床相关性不确定。
  • GFAP和NfL反映非特异性神经生物学过程,而非稳健的MG生物标志物。

研究设计与样本

  • 回顾性病例对照研究,纳入137例确诊MG患者和338例健康对照。
  • 临床分类遵循MGFA标准,抗AChR和抗MuSK抗体采用ELISA检测。
  • 血清GFAP和NfL采用全自动化学发光免疫分析法(Lumipulse G1200)定量。
  • 组间比较采用非参数检验,相关性采用Spearman分析,独立决定因素采用多变量线性回归评估。
  • 采用ROC曲线分析评估诊断性能。

主要发现

  • MG患者血清GFAP浓度高于对照(44.6 vs 29.6 pg/mL),与年龄强相关(r=0.64,p<0.0001),与抗体滴度无关。
  • 多变量回归中年龄是GFAP的主要独立决定因素(β=0.00827,p<0.0001),MG状态不是。
  • GFAP诊断性能中等(AUC=0.704)。
  • 年龄性别匹配分析中NfL在MG患者中轻度升高(30.2 vs 15.5 pg/mL;p=0.047)。
  • 两组中GFAP与NfL均呈中度正相关。

关键数值与推荐

  • GFAP:MG患者44.6 pg/mL vs 对照29.6 pg/mL。
  • GFAP与年龄相关系数r=0.64,p<0.0001。
  • 多变量回归GFAP的年龄β=0.00827,p<0.0001。
  • GFAP诊断MG的AUC=0.704。
  • NfL(年龄性别匹配):MG患者30.2 pg/mL vs 对照15.5 pg/mL,p=0.047。

临床怎么用

  • 血清GFAP和NfL不宜作为MG的常规诊断或疾病活动度生物标志物。
  • 解读GFAP结果时需考虑年龄和 sex 的混杂影响。
  • NfL轻度升高可能提示神经轴索受累,但尚不足以指导临床决策。

局限性

  • 回顾性病例对照设计,可能存在选择偏倚。
  • 对照组为非匹配健康人群,年龄和性别分布差异影响GFAP分析。
  • 未报告纵向数据,无法评估标志物与疾病活动度或预后的关系。
  • NfL仅在年龄性别匹配亚组中分析,样本量有限。
  • 单中心研究,结果外推性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction caused by antibodies against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). Although these antibodies enable diagnosis, they correlate poorly with disease activity and prognosis. Emerging data suggest that MG involves broader neuroimmune mechanisms beyond the peripheral synapse. Glial fibrillary acidic protein (GFAP), a marker of astroglial activation, and neurofilament light chain (NfL), a marker of neuroaxonal injury, have been proposed as circulating biomarkers in several neurological diseases. This study aimed to evaluate serum GFAP and NfL concentrations in MG patients and to assess its potential diagnostic utility. METHODS: In this retrospective case-control study, 137 patients with confirmed MG and 338 healthy controls were enrolled. Clinical classification followed MGFA criteria. Anti-AChR and anti-MuSK antibodies were measured by ELISA. Serum GFAP and NfL concentrations were quantified using a fully automated chemiluminescent immunoassay (Lumipulse G1200). Group comparisons were performed using non-parametric tests, correlations using Spearman analysis, and independent determinants assessed with multivariable linear regression. Receiver operating characteristic (ROC) curve analysis was performed to evaluate diagnostic performance. RESULTS: Serum GFAP concentrations were higher in MG patients than controls (44.6 vs 29.6 pg/mL) and strongly correlated with age (r = 0.64, p < 0.0001), but not with antibody titers. In multivariable regression, age was the main independent determinant of GFAP (β = 0.00827, p < 0.0001), whereas MG status was not. GFAP showed moderate diagnostic performance (AUC = 0.704). In an age- and sex-matched analysis, NfL concentrations were modestly higher in MG patients compared with controls (30.2 vs 15.5 pg/mL; p = 0.047). A moderate positive correlation between GFAP and NfL was observed in both groups. CONCLUSIONS: Circulating GFAP levels are elevated in MG but are primarily driven by age and sex rather than disease-specific mechanisms, limiting their diagnostic utility. NfL shows a modest increase, suggesting subtle neuroaxonal involvement; however, its clinical relevance remains uncertain. Together, these findings indicate that GFAP and NfL reflect non-specific neurobiological processes rather than robust biomarkers of MG.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Gambino CM, Agnello L, Scazzone C, et al. Exploring the role of circulating glial fibrillary acidic protein and neurofilament light chain in myasthenia gravis. Clin Chim Acta. 2026. PMID: 42081930. doi:10.1016/j.cca.2026.121052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。